Daily Roundup

XRF Scientific delivers impressive growth across the board

XRF Scientific Ltd is riding high after a stellar Q2, with revenue jumping 38% to $21.1 million and profit before tax climbing 30% to $4.4 million. The company's consumable and capital equipment divisions both fired on all cylinders, generating $5.6 million and $5.9 million respectively. Perhaps most encouraging is the turnaround at the new India office, which has already swung into profitability. Orbis products have been a particular standout, with sales surging 66% to $2.4 million. Precious metals product sales also climbed to $9.6 million, buoyed by positive recycling activity in the mining sector. Looking ahead, XRF expects the December quarter to be even stronger, bolstered by fresh revenue from the CGA acquisition—which is on track to begin production in December—and continued momentum from Orbis.

Baby Bunting shows resilience with refurbished stores leading the charge

Baby Bunting Group Ltd wrapped up its annual meeting with some solid numbers to celebrate. The retailer posted record sales of $556 million, up 6.5%, while comparable store sales growth came in at a respectable 3.5%. The real story, though, is what's happening in the stores themselves. The company completed 17 store refurbishments during the year, and those renovated locations are delivering an impressive 20% average sales lift. The gross margin expanded to 41.2%, reflecting better operational efficiency. For the year ahead, Baby Bunting is sticking with its guidance, expecting pro forma net profit after tax between $19 million and $21 million on total sales of $585 million to $600 million. The company also announced some leadership changes, with Gary Levin retiring and Richard Vincent joining the board.

PainChek accelerates US expansion with Sabra partnership

PainChek Limited is making serious headway in the American market. The company has expanded its footprint under its master services agreement with Sabra Health Care REIT from just two facilities to 23 communities across five operators. The focus remains squarely on assisted living and memory care—a market with an estimated 1.2 million potential license opportunity. PainChek is now targeting 808 memory care licenses and has set an ambitious goal to convert these contracts into implemented annual recurring revenue by the end of December. The company is also pursuing additional opportunities with other US assisted living and memory care operators.

Memphasys posts strong growth with international expansion

Memphasys Ltd reported invoiced revenues of $211,000 for the quarter, a healthy 41% jump from the previous period. The company has been busy building out its European distribution network with new agreements in Poland, the Nordic countries, and Central Asia. Regulatory approvals have also opened doors in Vietnam, Thailand, and Turkey, where the company is now taking orders. Repeat business from Italy, the UK, and the Middle East and North Africa region signals genuine demand from existing partners. The company recently appointed Arne Schierau as Director of Commercial Operations Europe and secured a $3.5 million funding agreement with Peters Investments to fuel growth. Memphasys is also exploring a potential FDA 510(k) pathway for its Felix product in the US market.

Raiz Invest addresses historical tax compliance issues

Raiz Invest Limited has identified historical tax compliance issues related to tax file number and Australian Business Number withholding and reporting obligations for certain funds offered through its platform since 2015. The company has engaged WTS Australia to conduct an independent expert review and has proactively notified both the Australian Taxation Office and the Australian Securities and Investments Commission. A remediation program is underway. The company has emphasized that customer funds remain secure and that no immediate action is required from customers. Further updates will be provided as the review and regulatory engagement progresses.